database / hormone
Abaloparatide
also known as Tymlos
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 76943386. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
A PTHrP(1-34) analogue with several substitutions including Aib, so it has no plain one-letter sequence.
Molecular data
| molecular formula | C174H300N56O49 |
|---|---|
| molecular weight | 3961 Da (PubChem) |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | subcutaneous |
| PubChem CID | 76943386 |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
PTH1R agonist selective for the RG conformation.
Reported targets: PTH1R
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| bone mineral density outcomes in trials | Abaloparatide and paclitaxel combination therapy Improves bone volume and tu… Journal of bone oncology 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT04974723 | Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal | COMPLETED | — |
| NCT03841058 | Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initia | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06154187 | Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteopor | UNKNOWN | PHASE3 |
| NCT04249232 | Abaloparatide and Pelvic Fracture Healing | COMPLETED | PHASE2 |
| NCT03746041 | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes | COMPLETED | PHASE1 |
Literature (8)
Abaloparatide and paclitaxel combination therapy Improves bone volume and tumor burden in Bone-Metastatic breast cancer — Journal of bone oncology 2026
•Abaloparatide is FDA-approved for osteoporosis but is not well characterized in patients with bone metastases.•Combination abaloparatide and paclitaxel reduced tumor and increased bone volume in an intratibial model of cancer in bone.•Abaloparatide alone did not impact tumor burden or bone volume in tumor limb.
open access ↗ · PMID 41798079 · DOI 10.1016/j.jbo.2026.100752
The effects of abaloparatide on acetabular bone mineral density and proximal femur strength in men with osteoporosis — Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41812602 · DOI 10.1016/j.jocd.2026.101686
Rapid fracture healing of the greater tuberosity fragment after shoulder hemiarthroplasty in a patient with daily abaloparatide injection: A case report — Bone reports 2026
We report a case of a 64-year-old woman who developed a 4-parts shoulder fracture-dislocation with peripheral nerve injury by the displaced fragment, during abaloparatide treatment. Following shoulder hemiarthroplasty, bone union at the greater tuberosity was achieved on postoperative day 16, with remodelling completed at 6 months postoperatively. This course was exceptionally favourable. Factors potentially contributing to the early bone union progression may include the coincidental administration of abaloparatide prior to trauma and the presence of peripheral nerve injury.
open access ↗ · PMID 41626402 · DOI 10.1016/j.bonr.2026.101899
The Efficacy and Safety of Abaloparatide in Osteoporosis: A Systematic Review and Meta-Analysis — Journal of clinical medicine 2026
Background/Objectives: Abaloparatide is an osteoanabolic therapy used in patients at high risk of fracture; however, the breadth of evidence across routes, comparators, and sequential strategies has not yet been comprehensively summarized. This study aimed to evaluate the efficacy and safety of abaloparatide for reducing fractures and improving bone mineral density (BMD) in adults with osteoporosis. Methods: Following PRISMA 2020, we searched PubMed, Embase, CENTRAL, and Web of Science (2016-2024) for randomized controlled trials and comparative real-world studies. Additional meta-analyses and network meta-analyses were included as contextual evidence but not pooled to avoid double-counting. Primary outcomes were vertebral, non-vertebral, and hip fractures; secondary outcomes included percentage change in BMD and safety endpoints. Random-effects models were used; heterogeneity, influence…
open access ↗ · PMID 41598611 · DOI 10.3390/jcm15020673
A thorough LC-MS/MS strategy to quantify abaloparatide in rat plasma: method development, validation and application — Analytical methods : advancing methods and applications 2025
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 40960186 · DOI 10.1039/d5ay01189b
The effects of abaloparatide on alveolar bone loss in postmenopausal osteoporotic rats with periodontitis — BMC oral health 2025
BACKGROUND: Abaloparatide is a second-generation osteoporosis drug that prevents bone loss and stimulates bone fromation. This study evaluated the effects of abaloparatide treatment on alveolar bone loss (ABL) in osteoporotic rats with periodontitis by immunohistochemical and microcomputed tomography (micro-CT) in rats with periodontitis and osteoporosis. METHODS: Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with [dose redacted] abaloparatide (PO-10), and PO treatment with [dose redacted] abaloparatide (PO-80). Bilateral ovariectomy was conducted in the osteoporosis groups. Three weeks after ovariectomy, experimental periodontitis was induced via Ligature. Abaloparatide was performed at the same time as the induction of experimental periodontitis. All rats were sacrificed at 30 days. ABL was dete…
open access ↗ · PMID 41023931 · DOI 10.1186/s12903-025-06915-1
Biological activation of prolonged delayed fracture healing following abaloparatide under stable circular external fixation: successful limb salvage of a Gustilo type III-C pilon fracture in severe immune thrombocytopenia-a case report — Journal of medical case reports 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42351259 · DOI 10.1186/s13256-026-06289-0
Abaloparatide-Zoledronate combination protects against 4-vinylcyclohexene diepoxide-induced postmenopausal osteoporosis in mice: an osteoanabolic-antiresorptive approach — Naunyn-Schmiedeberg's archives of pharmacology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41579168 · DOI 10.1007/s00210-026-04984-9
Related
Glucagon
hormone · 8 citations
Ghrelin
hormone · 8 citations
Oxytocin
hormone · 8 citations
Vasopressin
hormone · 8 citations
Gonadorelin
hormone · 8 citations
Kisspeptin-10
hormone · 8 citations